Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @DusoBruno
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DusoBruno
-
Bruno Achutti Duso proslijedio/la je Tweet
How to survive the fake news about cancerhttps://www.theguardian.com/science/2019/jul/14/cancer-fake-news-clinics-suppressing-disease-cure?CMP=share_btn_tw …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
sj Miller (
@drsjmiller) lends insight into our perception of gender and the distress that people with nonconforming gender identities often feel trying to fit into a binary world.#TEDMED 2018http://ow.ly/G1lC50unVCJHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Omloop Het Nieuwsblad: Woman cyclist stopped after catching men - CNNhttps://edition.cnn.com/2019/03/04/sport/cycling-women-belgium-intl-scli-spt/index.html …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
ESMO's Research Fellowships - Excellent opportunities for young oncologists to develop high-quality
#research projects in either translational or clinical research. More details here http://bit.ly/2GENPGL pic.twitter.com/GANRpuLpcG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bare, simple educational scheme by Aurélien Marabelle on why we avoid using medians when accessing outcomes in IO.
#TAT19pic.twitter.com/k4TZqwN86y
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
Interesting talks this morning at
#TAT2019, highlighting the biological rationale for combining CDK4/6i with PD-(L)1 blockade, as well as the potential detrimental effect of combining co-stimulatory receptor (OX40) agonists with PD-1 inhibitors.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This is such a clear view on how different cell niches may respond to different therapies (no wonder PR is our most common outcome on clinical trials). Thumbs up, Benjamin Izar.
#TAT19pic.twitter.com/kqwHKMr9ic
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ok, the concept of turning immunotherapy ‘cold’ tumors into ‘hot’ by chemo-induced mutations has seen better days, but when it comes to pushing MMRd at our favor for therapeutic purposes, what are your thoughts about it?
#TAT19@myESMOpic.twitter.com/eMMbSydxpO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Subtracting single cell copy number alteration baseline profile from after therapy analysis may give valuable info on specific acquired resistance mechanisms - a root cause method applied by Prof Johann De Bono at
#TAT19@myESMOpic.twitter.com/dit6E9xgNB
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
The University of Global Health Equity, a
@PIH initiative, is the world’s first medical school dedicated to global health equityhttp://hvrd.me/6xFm30nHNqaHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
Impassion can be a positive emotion but careless expression of it is inappropriate. With increasing interest in atezolizumab in breast cancer particularly after the
#SABCS18 oral presentation, here are my few thoughts....1/n@oncology_bg @VPplenarysesh@SABCSSanAntonioPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
Liquid biopsies for cancer have gained a new dimension. Beyond CTC, ctDNA or mRNA, now a functional assay that quantifies proteases secretion from CTC has been implemented. These outlier protease-secreting CTC may drive metastasis & immune evasion. http://www.pnas.org/content/early/2018/09/11/1803884115 …pic.twitter.com/URcNY3kRDh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
Our perspective on CIN and the tumor microenvironment out today in
@CellCellPress: the two sides of#inflammation#cGAS#STING in#cancer. It’s all context dependent - new ways to target CIN as a therapeutic vulnerability@Sloan_kettering@WeillCornellhttps://www.cell.com/cell/fulltext/S0092-8674(18)31043-2 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
Selective
#RET kinase inhibition for patients with RET-altered cancers http://bit.ly/2HvFFR7 pic.twitter.com/MtUGTxHlf2
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
Looking forward to the full release of the SOLAR-1 data. This trial testing the alpha-specific PI3K inhibitor BYL719+fulvestrant vs. fulvestrant in HR+/HER2-/PIK3CAmt
#breastcancer met its PFS endpoint. PIK3CAmt has been found in 35.7% of our breast ca pts.#precisionmedicinepic.twitter.com/kwHoHzd5ew
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
Exosomes are an underappreciated vector of body communication. Their impact in cancer was recently highlighted in melanoma when PDL1 + exosomes were identified as a source of resistance to
#immunotherapy Great@NEJM review: a must read ! https://www.nejm.org/doi/full/10.1056/NEJMra1704286?query=featured_home …pic.twitter.com/B4kv9hsSlO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
Ethnicity contributed to explain interindividual dissimilarities in gut microbiota composition...https://www.nature.com/articles/s41591-018-0160-1?sf196392365=1 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
More evidence that in the US, cancer outcomes are due to access and socioeconomic status which are largely normalized in cooperative group trials. Studies that do not consider wealth and geography in population outcomes are meaningless.https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2696871 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
BET inhibition + aPD-1
#immunotherapy in KRAS mutant#LungCancer Nice work from KK Wong in his new@nyulangone gig. FWIW I don't think it's going to be that easy in patients, but it's a neat conceptual framework for trials. In@AACR Cancer Immunol Res http://cancerimmunolres.aacrjournals.org/content/early/2018/08/07/2326-6066.CIR-18-0077 …pic.twitter.com/0DABYMMqZq
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bruno Achutti Duso proslijedio/la je Tweet
If only he had lived to transform US medical education and practice...https://twitter.com/EricTopol/status/1026155136630980609 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.